RLAY
Price:
$4.43
Market Cap:
$741.51M
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology re...[Read more]
Industry
Biotechnology
IPO Date
2020-07-16
Stock Exchange
NASDAQ
Ticker
RLAY
According to Relay Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 18.42. This represents a change of -8.17% compared to the average of 20.06 of the last 4 quarters.
The mean historical Current Ratio of Relay Therapeutics, Inc. over the last ten years is 38.32. The current 18.42 Current Ratio has changed 4.71% with respect to the historical average. Over the past ten years (40 quarters), RLAY's Current Ratio was at its highest in in the December 2020 quarter at 56.49. The Current Ratio was at its lowest in in the March 2019 quarter at 0.
Average
38.32
Median
35.11
Minimum
16.00
Maximum
61.78
Discovering the peaks and valleys of Relay Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 87.81%
Maximum Annual Current Ratio = 61.78
Minimum Annual Increase = -60.13%
Minimum Annual Current Ratio = 16.00
Year | Current Ratio | Change |
---|---|---|
2023 | 25.44 | 58.99% |
2022 | 16.00 | -60.13% |
2021 | 40.14 | -28.95% |
2020 | 56.49 | 87.81% |
2019 | 30.08 | -51.31% |
The current Current Ratio of Relay Therapeutics, Inc. (RLAY) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
27.19
5-year avg
33.63
10-year avg
38.32
Relay Therapeutics, Inc.’s Current Ratio is greater than Stoke Therapeutics, Inc. (5.09), greater than Pliant Therapeutics, Inc. (10.26), greater than Black Diamond Therapeutics, Inc. (5.55), greater than Arvinas, Inc. (4.17), greater than Day One Biopharmaceuticals, Inc. (14.62), greater than Mirati Therapeutics, Inc. (7.54), greater than Amylyx Pharmaceuticals, Inc. (4.55), less than Terns Pharmaceuticals, Inc. (32.99), greater than Apellis Pharmaceuticals, Inc. (4.36), less than Theseus Pharmaceuticals, Inc. (29.93), greater than aTyr Pharma, Inc. (6.07), greater than Century Therapeutics, Inc. (10.39), greater than Blueprint Medicines Corporation (3.32), greater than C4 Therapeutics, Inc. (6.31), greater than Monte Rosa Therapeutics, Inc. (6.03), greater than Nurix Therapeutics, Inc. (5.28), greater than Foghorn Therapeutics Inc. (4.77), less than Edgewise Therapeutics, Inc. (26.35), greater than Mineralys Therapeutics, Inc. (8.55), less than Cullinan Oncology, Inc. (24.46),
Company | Current Ratio | Market cap |
---|---|---|
5.09 | $702.34M | |
10.26 | $883.59M | |
5.55 | $138.07M | |
4.17 | $1.69B | |
14.62 | $1.33B | |
7.54 | $4.12B | |
4.55 | $309.15M | |
32.99 | $587.78M | |
4.36 | $4.31B | |
29.93 | $181.50M | |
6.07 | $131.12M | |
10.39 | $119.89M | |
3.32 | $6.06B | |
6.31 | $304.24M | |
6.03 | $579.96M | |
5.28 | $1.56B | |
4.77 | $348.01M | |
26.35 | $2.79B | |
8.55 | $653.96M | |
24.46 | $730.76M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Relay Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Relay Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Relay Therapeutics, Inc.'s Current Ratio?
How is the Current Ratio calculated for Relay Therapeutics, Inc. (RLAY)?
What is the highest Current Ratio for Relay Therapeutics, Inc. (RLAY)?
What is the 3-year average Current Ratio for Relay Therapeutics, Inc. (RLAY)?
What is the 5-year average Current Ratio for Relay Therapeutics, Inc. (RLAY)?
How does the current Current Ratio for Relay Therapeutics, Inc. (RLAY) compare to its historical average?